Manjari Lahiri
@SgRheumer
Followers
197
Following
382
Media
160
Statuses
494
Rheumatologist, A/Prof @NUSMedicine 🇸🇬 @NUHSofficial || @AIIMS_NewDelhi ‘90-‘99 🇮🇳 || #RheumTwitter🦴|| #MedEd || Mummy of 2 || Dreamer || Views my own
Singapore
Joined December 2010
RT @Aiims1742: @SirohiBhawna @BhatlaDr @aiims_newdelhi @dgafms_mod Congratulations to Dr. Bhatla from the AIIMS 1990 batch. We are proud to….
0
2
0
4-year data from TREAT EARLIER @TheLancetRheum. ⬇️ risk of seronegative RA for MTX arm (& 💉 IM triamcinolone). How about just the IM 💉 steroid ? . Somehow not really convinced that treating with MTX makes sense?. What do you think? 🤔 . #RheumTwitter .
0
0
1
Shucks 😭 didn't make it!.Oh well, keep trying💪. 😂. #ACR24.
Congrats to the influencers of #ACR24 & thanks for all your posts sharing knowledge from the conference!!! 🥳. @ACRheum @rheum_cat @RheumNow .@MithuRheum @EBRheum @noellealicia242 @NamrataRheum .@realcc @rheumarhyme #Rheumatology
1
0
0
So many options 🤩.But let's not forget that early diagnosis, close monitoring, improved adherence to treatment and minimising GC toxicity will probably have a larger impact in terms of absolute patient numbers and reach . #LupusNephritis .#Lupus.
✅ Current pipeline of investigational agents / drug development in #Lupus, updated with #ACR2024 data ⬇️ What would you add? Which ones are the most promising? There is truly hope for patients with #SLE. Please do let me know if I have forgotten something & I will reupdate.
0
0
2
Not investing any time soon 😅 but this is a great summary!.
B-cell Depletion Race in AID 1.Identifying key players in this race could present an outstanding investment opportunity. Here’s how I approach this emerging field:.$SANA $IPSC $FATE $CRBU $CRSP $ALLO $PSTX $ACET $TAK $NKTX $LEGN $NVS $BMY $AZN $AMGN $RHHBY $MRK $CGEM $IGMS $XNCR
0
0
1
RT @EBRheum: All-caps abstract text throw-down by Michelle Petri re:fractures in SLE 😆 . I keep saying this; our obsesssion with vitamin d….
0
7
0
RT @NEJM: Sarcoidosis is a granulomatous disorder that affects people of all racial and ethnic backgrounds. The pathogenesis of sarcoidosis….
0
64
0
Clinical year in PREVIEW.Grace Wright @AWIRGROUP .#ACR24 . 3/3 . 💥Anti-obesity meds in RA/ AID.Observational databases (FORWARD - pan-US, community practices). 💪🏽 Improved PRO, APR .👉🏽But ONLY in obese pts.❓⬇️CV risk.New paradigm of combination Rx?.
0
1
2
Clinical year in PREVIEW.Grace Wright @AWIRGROUP .#ACR24 . 2/3. 💥Cell Rx in SLE.💡Autologous anti-CD19 B.💡NEX-T.💡CD3XCD19 TCE. Safety ✅ low CRS, no ICANS, deep depletion.👎🏽infections, neutropenia.
1
1
2
Clinical year in PREVIEW.Grace Wright @AWIRGROUP .#ACR24 . 1/3. 💥Biomarkers in SLE.Non-invasive urinary panel predicts BOTH active proliferative LN AND response ✅. 💥GC sparing in SLE.Disruption of E3-X novel E3-ligase ⬆️GILZ.
1
1
4
Late breaking L19.Alexei Grom.#ACR24 . Emapalumab: anti IFN y Ab, MAS in Still’s dz. 💡Data pooled from 2 obs studies, n=49, mostly kids.✅ 1° outcome CR of ALL MAS criteria=53%, 69% if LDH excluded, 82% investigator determined remission, 95% survival. 👎🏽TEAE = viral infections🦠
0
2
1
RT @ARD_BMJ: 🔍 Why CAR-NK therapy works?. 💥 Deep B-cell depletion + naïve B-cell reset. 💥 Complement normalization (C3, C4). 💥 Anti-dsDNA a….
0
3
0
RT @ARD_BMJ: ⁉️ CAR-NK therapy will redefine treatments for lupus ⁉️. ✅️ Targeted, very safe immune modulation with off-the-shelf availabil….
0
5
0
Late breaking L17.#ACR24 . More excitement in the cellular Rx field!.N=22 refractory lupus.open label (China). ✨CAR-NK (not T).✨Allogenic!. Avg F/up 7m, max 14m. ⬇️ SLEDAI2K, PGA.SRI4 ✅.DORIS remission 6m=50-%, 12m=💯. ✨With NO CRS >=2/ ICANS/ infections!. Needs replication!
0
2
2
Who thinks MDA5 DM should be a category of its own? 🙋🏻♀️. #ACR24 .@ACRheum .@ARD_BMJ .@ACR_Journals.
Bohan & Peter criteria out!. Current classification ➡️ clinical & serology .iDM.IMNM.anti-synthetase.IIM.(ICI-induced #myosotis). but @MozaffarTahseen argues that myopathology is crucial. Perifascicular atrophy/ MXA staining = DM.Even if no skin manifestation 🤷🏻♀️. #ACR24
0
0
0